Sugi Predict

Sugi Predict / Compounds / SCHEMBL4438019

SCHEMBL4438019

SCHEMBL4438019

CN(C)CCN1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.62
▸ GFER P55789 4/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ GAA P10253 3/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ RAD52 P43351 1/20 0.62
▸ ALDH1A1 P00352 3/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ ADRA2C P18825 1/20 0.58
▸ PTK2B Q14289 1/20 0.58
▸ ESR2 Q92731 1/20 0.58
▸ HTT P42858 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ SIGMAR1 Q99720 2/20 0.48
▸ CASP6 P55212 1/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6151797 1.00 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL4499003 0.90 KDM4E (0.58) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL24123575 0.86 L3MBTL3 (0.48) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL21561087 0.85 MAPT (0.58) MAPTSIGMAR1NPSR1HTR7DRD2
SCHEMBL23570939 0.84 HRH3 (0.46) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL15599350 0.83 HTR7 (0.51) SIGMAR1HTR7DRD2
SCHEMBL374548 0.81 KDM4E (0.73) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL6151501 0.80 GAA (0.67) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL4963492 0.80 SIGMAR1 (0.63) MAPTSMN1; SMN2ALDH1A1LMNAMAPK1
SCHEMBL4960579 0.80 LMNA (0.67) ALDH1A1LMNASIGMAR1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113614087-B WEE1 inhibitor and preparation and application thereof 首药控股(北京)股份有限公司 2023-06-02 — — CN disclosed
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 — — WO disclosed
US-20220194960-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF Shouyao Holdings (beijing) Co., Ltd. (CN) 2022-06-23 — — US disclosed
EP-3943496-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF Shouyao Holdings (Beijing) Co., Ltd. (CN) 2022-01-26 — — EP disclosed
EP-3943496-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF Shouyao Holdings (Beijing) Co., Ltd. (CN) 2022-01-26 — — EP disclosed
EP-3466948-B1 FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) 2021-01-20 — — EP disclosed
WO-2020192581-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF 首药控股(北京)有限公司 2020-10-01 — — WO disclosed
WO-2020192581-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF 首药控股(北京)有限公司 2020-10-01 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-10544144-B2 Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOL (CN) 2020-01-28 — — US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2681221-A1 TRICYCLIC INHIBITORS OF KINASES AbbVie Inc. (US) 2014-01-08 — — EP disclosed
WO-2013126656-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-08-29 — — WO disclosed
US-20130225589-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES ABBVIE INC. (US) 2013-08-29 — — US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
WO-2012161812-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-11-29 — — WO disclosed
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-08-30 — — US disclosed
EP-2040546-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-01 — — EP disclosed
WO-2007149427-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225589-A1 PYRIDOPYRIMIDINONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 MAPT 2447/4885GFER 3162/4885KDM4E 585/4885
US-20120220572-A1 TRICYCLIC INHIBITORS OF KINASES WEE1, WEE2, CDK1 MAPT 2484/4885GFER 4085/4885KDM4E 482/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK MAPT 470/4885GFER 3828/4885KDM4E 1662/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 MAPT 634/4885GFER 3779/4885KDM4E 1843/4885
US-20220194960-A1 WEE1 INHIBITOR AND PREPARATION AND USE THEREOF WEE1, WEE2, RCE1 MAPT 25/4885GFER 1584/4885KDM4E 608/4885
US-10544144-B2 Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof FGFR1, FGFR4, FGFR2 MAPT 3964/4885GFER 4146/4885KDM4E 804/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885GFER 3792/4885KDM4E 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.